Welcome to our dedicated page for Gossamer Bio SEC filings (Ticker: GOSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gossamer Bio, Inc. (GOSS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), and its filings offer detailed insight into this strategy.
Through current reports on Form 8‑K, Gossamer Bio reports material events such as quarterly financial results, stockholder meeting outcomes, and significant transactions. Recent 8‑K filings have described results of operations and financial condition, approval of amendments to its 2019 Incentive Award Plan, and the option agreement and plan of merger that grant Gossamer Bio the right to acquire Respira Therapeutics and its pulmonary hypertension candidate RT234. These documents outline share issuances, potential milestone payments, and other key terms.
Investors can also use this page to locate references to the company’s incentive equity plans, employment inducement awards, and stockholder voting results, which appear in filings related to annual meetings and compensation arrangements. While Forms 10‑K and 10‑Q are not reproduced here, they are accessible through EDGAR and provide comprehensive information on research and development expenses, collaboration revenue, cash resources, and risk factors tied to seralutinib and the broader pipeline.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the main points of lengthy reports, track how new equity issuances affect capital structure, and see how clinical and business milestones are reflected in Gossamer Bio’s regulatory record. Real-time updates ensure that new 8‑K, 10‑Q, 10‑K, and Form 4 insider transaction filings for GOSS are surfaced as they are posted to EDGAR, helping users follow the company’s evolving disclosure history.
Gossamer Bio, Inc. (GOSS) – Form 4 filing dated 06/26/2025
Non-employee director Skye Drynan received an option grant for 115,000 shares of common stock with an exercise price of $1.36 per share on 06/25/2025. The award was made under the company’s Non-Employee Director Compensation Program.
The option vests 100 % on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of stockholders, subject to continued board service. The director now beneficially owns 115,000 derivative securities; no common shares were reported as acquired or sold. Ownership is listed as direct.
No cash transactions, open-market purchases, or sales were disclosed. The filing represents a routine equity incentive and does not indicate any change in the company’s operational outlook or financial condition.
Form 8-K Overview: On 25 June 2025 Gossamer Bio (Nasdaq: GOSS) disclosed the voting results of its 2025 Annual Meeting and the adoption of an Amended & Restated 2019 Incentive Award Plan.
Board Elections: Class I directors Thomas Daniel, Sandra Milligan and Steven Nathan were re-elected for terms expiring in 2028. Support ranged from 80%–88% of votes cast, with 47.1 million broker non-votes recorded.
Auditor Ratification: Ernst & Young LLP was ratified as independent registered public accounting firm for fiscal 2025 by 176.5 million votes for versus 0.1 million against, indicating near-unanimous confidence.
Say-on-Pay: Compensation of named executive officers received strong advisory backing—125.4 million for (≈96%) and 3.8 million against.
Equity Incentive Plan: The Amended & Restated 2019 Incentive Award Plan passed with 87.8 million for and 41.5 million against (≈67.7% approval, excluding broker non-votes). The comparatively higher dissent signals some shareholder concern over potential dilution or pay practices, though the proposal ultimately carried.
Materiality: No financial performance metrics, strategic transactions, or guidance updates were included. The filing is primarily governance-related; its impact centers on confirming board stability, auditor continuity and refreshed equity compensation capacity.